P. Schnabel (Heidelberg, Germany), S. Diederichs (Heidelberg, Germany)
Inhibition of hypoxia-induced phenotype alterations through epithelial-mesenchymal transition (EMT) in lung cancer by gene modulation of phosphorylation sites in tumor suppressor PTEN
N. Hashimoto, Y. Hasegawa (Nagoya, Japan)
|  |
Loss of orphan G protein coupled receptor GPRC5A is associated with metastatic disease and poor survival in patients with adenocarcinomas of the lung
J. K. Hennigs, S. Minner, J. Müller, H. J. Baumann, C. Bokemeyer, G. Sauter, H. Klose (Hamburg, Germany)
| |
RARβ2 methylation level in blood for lung cancer assessment
A. Ponomaryova, E. Rykova, N. Cherdyntseva, T. Skvortsova, A. Dobrodeev, A. Zav‘yalov, S. Tuzikov, V. Vlassov, P. Laktionov (Tomsk, Novosibirsk, Russian Federation)
| |
Quantitative methylation profiles of multiple genes in patients with non-small cell lung cancer and its association with clinicopathological correlations
M. Kontic, J. Stojsic, D. Jovanovic, V. Bunjevacki, S. Ognjanovic, S. Puumala, H. Nelson (Belgrade, Republic Of Serbia; Minneapolis, Sioux Falls, United States Of America)
|  |
The risk of distant metastases and prognosis prediction in early stage squamous cell lung cancer (SqCLC) by means of 3 microRNAs expression assessment
M. Skrzypski, R. Dziadziuszko, A. Szymanowska, E. Jassem, P. Czapiewski, W. Biernat, W. Rzyman, R. Pawlowski, J. Jassem (Gdansk, Poland)
| |
The clinical significance of plasma DNA quantification in NSCLC
A. Szpechcinski, K. Maszkowska-Kopij, W. Kupis, J. Zaleska, E. Radzikowska, R. Struniawski, E. Puscinska, T. Orlowski, P. Sliwinski, K. Roszkowski-Sliz, J. Chorostowska-Wynimko (Warsaw, Poland)
| |
Very early detection of small clones harbouring EGFR mutations in NSCLC by 2nd generation sequencing
C. Vollbrecht, F. Mairinger, S. Trajanoski, I. Halbwedl, T. Maierhofer, G. Michelitsch, E. Stacher, M. Filipits, K. Schmid, J. Kollmeier, T. Mairinger, H. Popper (Senftenberg, Berlin, Germany; Graz, Vienna, Austria)
| |
Evaluation of highly sensitive PNA-LNA PCR clamp method for EGFR L858R mutation detection in lung adenocarcinoma patients
M. Skronski, T. Tanaka, A. Szpechcinski, R. Langfort, T. Orlowski, K. Hagiwara, J. Chorostowska-Wynimko (Warsaw, Poland; Moroyama-machi, Japan)
| |
Evaluation of four different molecular methods for EGFR mutation analysis in exon 18, 19 and 21
A. Streubel, A. Roth, S. Stephan-Falkenau, O. Landt, C. Götz, T. Mairinger (Berlin, Germany)
| |
Non-coding RNA as functional player and molecular marker in lung cancer
M. Polycarpou-Schwarz, T. Gutschner, S. Grund, A. Warth, H. Zabeck, C. Hildenbrand, M. Baas, M. Meister, T. Muley, P. Schirmacher, H. Hoffmann, P. Schnabel, S. Diederichs (Heidelberg, Germany)
| |
Polymorphisms A1026G and G369C of CDKN1A/p21 and p53 genes in lung cancer
A. I. Dmitrieva, I. A. Kuznetsova, S. S. Rakitin, V. V. Novitskiy (Tomsk, Russian Federation)
| |
Proteinase inhibition regulates the anti-tumor activity of PAI-1 towards lung and prostate cancer cells
A. Rozy, M. Kedzior, J. Chorostowska-Wynimko, P. Jagus, A. Szpechcinski, E. Skrzypczak-Jankun, J. Jankun (Warsaw, Poland; Toledo, United States Of America)
| |
Identification of p-stage I NSCLC patients with high risk of recurrence and poor prognosis by tumor marker index (TMI)
T. Muley, H. Hoffmann, H. Dienemann, M. Thomas, F. Herth, M. Meister (Heidelberg, Germany)
| |
Expression profiling in hypoxic non-small cell lung cancer explants reveals a four-gene hypoxia signature
K. Leithner, C. Wohlkoenig, E. Stacher, J. Lindenmann, F. M. Smolle-Jüttner, H. H. Popper, A. Hrzenjak, A. Olschewski, H. Olschewski (Graz, Austria)
| |
Contribution of immunohistochemical (IHC) markers to the diagnosis of pulmonary carcinoids
T. Zahel, A. Warth, E. Herpel, B. Goeppert, A. Stenzinger, S. Krysa, H. Hoffmann, P. Schirmacher, P. Schnabel (Heidelberg, Germany)
| |
Genetic polymorphism of alpha 1 antytrypsin and glutathione S transferase and lung cancer risk
A. Catana, R. Popp, M. Pop, M. Porojan, V. Pop, A. Trifa, F. Petrisor, M. Farcas (Cluj Napoca, Romania)
| |